ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jan 11, 2023 22:00 JST
Source:
HighTide Therapeutics Inc.
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)
ROCKVILLE, MD and SHENZHEN, CHINA, Jan 11, 2023 - (ACN Newswire) - HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH").
This double-blind, randomized, placebo-controlled, multicentre Phase 2b study will evaluate the effect of HTD1801, 1250 mg twice daily (BID), compared to placebo BID on histologic improvement in adult subjects with NASH and liver fibrosis who also have type 2 diabetes mellitus ("T2DM") or pre-diabetes. The study will enroll approximately 210 subjects with biopsy-confirmed NASH and evidence of stage 2 or stage 3 liver fibrosis. Subjects will receive HTD1801 for up to 60 weeks.
"Nonalcoholic fatty liver disease ("NAFLD") is the most prevalent chronic liver disease worldwide with a global prevalence of 25.2% to 29.8%. Of those with NAFLD, about 20% have NASH. Patients with NASH and T2DM or prediabetes are at increased risk of progressive liver disease and cardiometabolic complications," said Dr. Liping Liu, founder and Chief Executive Officer of HighTide. "This first patient dosing marks a key milestone for the development of HTD1801 for the treatment of patients with NASH, building on data from our Phase 2a study which showed HTD1801 was associated with meaningful improvements in liver fat, markers of liver Injury and fibrosis as well as cardiometabolic factors (HbA1c, lipids, and weight) after 18 weeks."
About NASH
NASH, a severe form of nonalcoholic fatty liver disease (NAFLD), is a chronic, complex liver disease characterized by hepatitis - inflammation of the liver - and liver cell damage, which can lead to fibrosis of the liver. NASH can also lead to cirrhosis and liver cancer. NASH patients with T2DM or impaired glucose tolerance are more likely to progress to more severe disease and to develop complications that lead to increased mortality. Prevalence of NASH is on the rise and may soon surpass hepatitis C as a cause for liver transplant in the U.S. and Europe. Currently, there are no approved therapies for NASH.
About HighTide Therapeutics
HighTide is a globally integrated clinical-stage biopharmaceutical company focusing on the discovery and development of novel multifunctional therapies for metabolic and digestive diseases with significant unmet medical needs. The company's lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in clinical development for the treatment of type 2 diabetes (T2DM), nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC). HTD1801 has received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program. For more information, please visit www.hightidetx.com.
Contacts
Nadia Gao
ir@hightidetx.com
Source: HighTide Therapeutics Inc.
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Honda to Relocate the Base of its Rugby Team Activities
Sep 19, 2024 15:05 JST
Renewal of Compact CO2 Capture System "CO2MPACT(TM)" Series
Sep 19, 2024 14:35 JST
The world's first commercial copper die-cast rotor for railway traction motors
Sep 19, 2024 13:57 JST
NEC Secures Fifth Consecutive Worldwide Partner of the Year Award from Juniper Networks
Sep 19, 2024 13:08 JST
Fujitsu and Stellar Science Foundation form partnership agreement to foster innovation by supporting young researchers
Sep 19, 2024 10:31 JST
Approval in Principle (AiP) Acquired from Two Classification Societies for Low-Pressure Type Liquefied CO2 Carriers undergoing Pursuit of Standardization toward Realization of Large-Scale International Transportation from 2028 onwards
Sep 18, 2024 18:02 JST
Europe's First Post-Combustion Carbon Capture Plant Starts Operation with MHI Technology as part of the Ravenna CCS Project, Phase 1
Sep 18, 2024 17:24 JST
Eutelsat and Mitsubishi Heavy Industries Reach Agreement for Multiple Launches
Sep 18, 2024 17:19 JST
NEC Orchestrating Future Fund invests in Sakana AI to promote development of generative AI
Sep 18, 2024 13:02 JST
IHI, Fujitsu, and Mizuho Bank form agreement to launch joint business venture to provide total support scheme for J-Credit
Sep 18, 2024 11:28 JST
JCB and Azer Turk Bank launch JCB merchant acquiring operations across the Republic of Azerbaijan
Sep 17, 2024 17:00 JST
Fuji frustration for TOYOTA GAZOO Racing
Sep 17, 2024 15:01 JST
Japan International Aerospace Exhibition 2024: Japan's largest comprehensive aerospace industry exhibition
Sep 17, 2024 12:00 JST
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Sep 17, 2024 10:08 JST
DENSO Wins Medals at 47th WorldSkills Competition
Sep 16, 2024 19:54 JST
Mitsubishi Corporation and ExxonMobil sign Project Framework Agreement to advance world's largest low-carbon hydrogen project
Sep 13, 2024 20:07 JST
MFJ All Japan Trial Championship: Team HRC Competes with RTL ELECTRIC Trial Bike
Sep 13, 2024 17:22 JST
NEC uses AI to analyze the trustworthiness of information and support fact-checking
Sep 13, 2024 10:18 JST
DENSO to Transfer All Its NiPPA Shares to Nippon Mirai Capital
Sep 13, 2024 09:59 JST
Femto Technologies Regains Compliance With Nasdaq Minimum Bid Price Requirement
Sep 12, 2024 22:00 JST
More Latest Release >>
Related Release
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies, Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801)
September 11 2024 11:34 JST
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)
June 21 2024 18:30 JST
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
June 05 2024 09:00 JST
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
January 05 2023 18:00 JST
AJG Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis
November 17 2022 08:00 JST
American Journal of Gastroenterology Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis
November 16 2022 23:00 JST
More Press release >>